WO2017095267A1 - Anticorps bi-spécifiques contre cd3*cd19 - Google Patents

Anticorps bi-spécifiques contre cd3*cd19 Download PDF

Info

Publication number
WO2017095267A1
WO2017095267A1 PCT/RU2016/000827 RU2016000827W WO2017095267A1 WO 2017095267 A1 WO2017095267 A1 WO 2017095267A1 RU 2016000827 W RU2016000827 W RU 2016000827W WO 2017095267 A1 WO2017095267 A1 WO 2017095267A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
lymphoma
antibody
cells
leukemia
Prior art date
Application number
PCT/RU2016/000827
Other languages
English (en)
Russian (ru)
Inventor
Александр Юрьевич ВИШНЕВСКИЙ
Андрей Павлович КАРПОВ
Максим Валерьевич ЛЫКОВ
Антон Николаевич МОРОЗОВ
Original Assignee
Общество С Ограниченной Ответственностью "Международный Биотехнологический Центр "Генериум" (Ооо "Мбц "Генериум")
Александр Юрьевич ВИШНЕВСКИЙ
ПЕТРОВ, Андрей Владимирович
Андрей Павлович КАРПОВ
ПОТЕРЯЕВ, Дмитрий Александрович
Максим Валерьевич ЛЫКОВ
РУЧКО, Сергей Валериевич
Антон Николаевич МОРОЗОВ
ФАБРИЧНЫЙ, Игорь Павлович
ХАМИТОВ, Равиль Авгатович
ШУСТЕР, Александр Михайлович
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Международный Биотехнологический Центр "Генериум" (Ооо "Мбц "Генериум"), Александр Юрьевич ВИШНЕВСКИЙ, ПЕТРОВ, Андрей Владимирович, Андрей Павлович КАРПОВ, ПОТЕРЯЕВ, Дмитрий Александрович, Максим Валерьевич ЛЫКОВ, РУЧКО, Сергей Валериевич, Антон Николаевич МОРОЗОВ, ФАБРИЧНЫЙ, Игорь Павлович, ХАМИТОВ, Равиль Авгатович, ШУСТЕР, Александр Михайлович filed Critical Общество С Ограниченной Ответственностью "Международный Биотехнологический Центр "Генериум" (Ооо "Мбц "Генериум")
Priority to EA201890805A priority Critical patent/EA036905B1/ru
Publication of WO2017095267A1 publication Critical patent/WO2017095267A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Definitions

  • the invention relates to biotechnology and, in particular, can be used in medicine and the pharmaceutical industry for the manufacture of a medicament for the treatment of B-cell disease, depletion of B-cells or slowing the development of a pathological condition associated with B-cell disorders.
  • Bispecific antibodies (BAPs) against CD3 * CD19 are currently being developed primarily for the treatment of malignant diseases of B cells or depletion of B cells, including non-Hodgkin’s lymphoma (WO2010037835, RU2228202), B-cell leukemia (RU2008129080), and acute lymphoblastic childhood leukemia (WO20100052013) H T.fl.
  • BAPs act as adapters that physically connect T cells with tumor cells and trigger a powerful signaling cascade of the T-cell receptor complex by binding to the invariant component of the CD3 T-cell receptor.
  • the second (target) antigen-specific fragment recognizes CD 19, i.e. BAP can connect a T cell and a cancer cell by simultaneously binding to CD3 and the target antigen.
  • the activation and proliferation of T cells, the formation of a cytolytic synapse with the release of cytotoxic granules, and the secretion of cytokines occur.
  • Targeted lysis of cancer cells includes perforation of the target cell membrane involving perforin and subsequent granzyme-induced apoptosis. It should be noted that after binding to T cells, BAPs recognize antigens on the surface of the cancer cell in the same way as conventional monospecific antibodies. Thus, it is possible to redirect cytotoxic function of T cells against tumor cells, and BAP activity is already observed at relatively low (picomolar) concentrations. Binding of BAT only to a T cell in the absence of a target cell does not cause T cell activation.
  • bispecific antibodies known from the prior art (Blood, (ASH Annual Meeting Abstracts), 2009, 114: 840) indicate that the effective therapeutic concentration of drugs derived from the use of multivalent antibodies is significantly lower compared to classic anti-cancer antibodies drugs. This contributes to good tolerance, the possibility of implementing long-term courses of treatment and reducing the risk of side effects. In addition, the required volume and production cost of bespecifically antibodies is lower. Therefore, the creation of such antibodies will significantly reduce the scale and cost of producing drugs based on them and, most importantly, make these drugs available to all patients in need of such therapy.
  • Blinatumomab consists of two domains: the anti-C019 scFv domain from the HD37 hybridoma and the anra-CD3 scFv domain from the OKTZ hybridoma. To obtain the antibody, the VLCD 19-VHCD 19-VHCD3-VLCD3 DNA fragment is expressed in DHFR-negative CHO cells (patent RU2228202).
  • Blinatumomab in comparison with full-sized antibodies, has a relatively small molecular weight (55 kDa versus 155 kDa), which is why it is rapidly eliminated from the bloodstream. Therefore, to achieve stable concentrations of the drug in the blood, continuous intravenous administration of the drug is used for 2-4 weeks per cycle (in a two-week regimen - an dropper, two weeks - a break), which is quite difficult for the patient to tolerate.
  • BiTE® antibodies demonstrate high efficacy of redirected lysis of cells expressing the tumor target antigen.
  • EC50 values for BiTE® antibodies generally range from 0.1 to 50 pM (Bauerle P.A. and Reinhardt C. (2009) Cancer Res. 69 (12), pp. 4941-4944). Powerful cytolysis of tumor cells is necessary in order to cause a pharmacologically desired effect.
  • Rader C Rader C.
  • BiTE® format reports that the powerful lytic ability of the BiTE® format is explained by (1) its small size, which brings the target and effector cells in close proximity, allowing the formation of cytolytic synapses, and (2) its monovalent involvement of the TCR complex, which prevents systemic activation of effector cells in the absence of target cells (Rader C. (2011), Blood, 117 (17), pp. 4403-4404).
  • the prior art describes that the BiTE® class of bispecific antibodies typically has 100-10000 times higher tumor cell lysis efficiencies relative to other bispecific formats and full IgGl monoclonal antibodies (Wolf et al. (2005) Drug Discov Today 10 ( 18), pp. 1237-1244).
  • the present invention solves the problem of obtaining a bivalent antibody against CD3 * CD19, convenient to use and obtain compared with blinatumomab and at the same time highly effective in treating malignant diseases of B cells, depletion of B cells or slowing the development of pathological conditions associated with B- cellular disorders.
  • bispecific molecules in comparison with the blinatumomab antibody (MT-103), are characterized by an increased half-life and are easy to obtain.
  • properties of the indicated antibody as enhanced cytotoxic effect and high bioavailability even with subcutaneous administration at the level of 60% were even more unexpected for the team of authors.
  • the latter characteristic is especially important, since until now, due to the low bioavailability, antibody preparations have been administered mainly via the intravenous route, which is more complex and less comfortable for the patient.
  • the increased half-life, high efficiency and bioavailability with subcutaneous administration will reduce the frequency of administration of the drug and increase the convenience of its use.
  • the first object of the present invention is a recombinant monoclonal bispecific anti-CD3 * CD19 antibody comprising two disulfide-linked chains, each of which consists of the following domains: VL (CD3) -Ll-VH (CD19) -L2-VL (CD19 ) -L3-VH (CD3) -H-CH2-CH3 (IgG), where VL (CD3), VL (CD19), VH (CD3) and VH (CD19) are the variable domains of the light and heavy chains of antibodies against CD3 and CD 19, respectively, LI, L2, L3 are linker sequences, H is the hinge region of IgG immunoglobulin and CH2-CH3 (IgG) is the constant region of the Ig immunoglobulin Fc domain G.
  • said constant region of the IgG immunoglobulin Fc domain is preferably a constant region of the IgG2 immunoglobulin Fc domain and contains the sequence shown in SEQ ID NO: 5.
  • the linker sequences LI, L2, L3 preferably have a length of 5-15 amino acids and have sequences according to essentially corresponding to the sequences presented in SEQ ID NO: 6, 7, 8, respectively.
  • the hinge region of the IgG immunoglobulin essentially corresponds to the sequence shown in SEQ ID NO: 9.
  • the specified antibody preferably has a half-life in blood, increased compared with the half-life of pancreatitis, measured in essentially similar conditions. Moreover, the half-life in blood of an antibody of the invention may be more than 40 hours. Moreover, the specified antibody preferably, but not necessarily has an amino acid sequence essentially corresponding to the sequence presented in SEQ ID NO: 10.
  • the following objects of the present invention are a nucleic acid encoding a chain sequence of the specified bispecific anti-CD3 * CD19 antibody of the invention, and a vector containing it.
  • the vector may be a vector for expressing a bispecific anti-CD3 * CD19 antibody in a host cell of the invention, comprising the aforementioned nucleic acid operably linked to nucleotide sequences enabling heterologous expression in the host cell.
  • the specified vector may be a cloning vector containing the above nucleic acid, and flanking its restriction sites, allowing you to cut the specified nucleic acid using suitable restriction enzymes.
  • the vector is an expression plasmid pRA1451 characterized by the following features:
  • Accl 6490 IO
  • Agel 460 IO
  • Apal 995 IO
  • BmgBI 3270 IO
  • Bsml 7269 IO
  • EcoRV 6457 i. O.
  • Hindlll 1590 I.O.
  • Notl 11146 I.O.
  • Pfol 11021 I.O.
  • Pmll 5699 I.O.
  • Spel 4622 I.O.
  • Swal 6466 acting
  • Tthl 111 10585 acting).
  • Another object of the present invention is a host cell containing a nucleic acid of the invention or a vector for expressing a bispecific anti-CD3 * CD19 antibody of the invention in a host cell.
  • the specified cell can be both prokaryotic and eukaryotic cells.
  • said cell may be a mammalian cell, in particular a Chinese hamster cell.
  • a further object of the present invention is a method for producing a bispecific anti-CD3 * CD19 antibody of the invention, comprising at least culturing a host cell of the invention under conditions that express the anti-CD3 * CD1 antibody of the invention and isolating the resulting product.
  • Another object of the present invention is a method for purifying an anti-CD3 * CD19 antibody of the invention, comprising at least one chromatography step under conditions providing a preparation of an anti-CD3 * CD19 antibody of the invention, substantially free of host cell impurities.
  • the specified method may further include a centrifugation step, preferably performed before the chromatography step, and another chromatography step.
  • the first chromatography step is preferably, but not necessarily, performed using a protein A sorbent
  • the second chromatography step is a cation exchange chromatography step.
  • the next object of the present invention is the use of antibodies against CD3 * CD19 according to the invention for the treatment of b-cell diseases, depletion of b-cells or slow the development of pathological conditions associated with b-cell disorders.
  • Said use comprises administering an antibody of the invention to a patient preferably, but not necessarily intravenously or subcutaneously.
  • the antibody is administered to the patient in a therapeutically effective amount.
  • Another object of the invention is a pharmaceutical composition for treating B-cell disease, depleting B-cells or slowing down the development of pathological conditions associated with B-cell disorders, comprising, as an active component, an anti-CD3 * CD19 antibody of the invention in a therapeutically effective amount and a pharmaceutically acceptable carrier.
  • the next object of the present invention is a method of treating B-cell disease, depletion of B-cells or slowing the development of pathological conditions associated with B-cell disorders, comprising administering to a patient in need thereof an effective dose of an anti-CD3 * CD19 antibody of the invention, or an effective amount pharmaceutical compositions of the invention.
  • B-lymphoblastic lymphoma B-cell acute lymphoblastic leukemia from progenitor cells
  • B-cell tumors from peripheral (mature) B-lymphocytes, including: B-cell chronic lymphocytic leukemia / lymphoma from small lymphocytes (lymphocytic lymphoma); B-cell prolymphocytic leukemia; lymphoplasmacytic lymphoma; splenic lymphoma of the marginal zone; hairy cell leukemia; plasma cell myeloma / plasmacytoma; extranodal B-cell lymphoma of the marginal zone of the MALT-type; nodal B-cell lymphoma of the marginal zone; follicular lymphoma; mantle cell lymphoma; diffuse B-large cell lymphoma; media
  • FIG. 1 Schematic representation of the construction of antibodies GNR-047
  • FIG. 2. The design scheme of the expression vector
  • FIG. 3 Map of expression vector pRA1451
  • FIG. 4 Analysis of the ability of the GNR-047 antibody and MT-103 antibody to bind the native CD3 receptor on the Jurkat cell line and CD 19 receptor on the Raji cell line
  • FIG. 5a Study of the pharmacokinetic characteristics of the GNR-047 antibody when administered intravenously at a dose of 0.5 mg / kg
  • FIG. 56 The study of the pharmacokinetic characteristics of the MT-103 antibody when administered intravenously at a dose of 0.5 mg / kg
  • FIG. 6a A study of the pharmacokinetic characteristics of the GNR-047 antibody when administered subcutaneously at a dose of 2.0 mg / kg
  • FIG. 66 A study of the pharmacokinetic characteristics of the MT-103 antibody when administered subcutaneously at a dose of 2.0 mg / kg
  • FIG. 7. Change in the average tumor volume during the study
  • recombinant monoclonal bispecific anti-CD3 * CD19 antibody used in accordance with the present invention includes antibodies that specifically bind to both CD3 and CD 19, which are obtained using recombinant technologies.
  • Antibody against CD3 * CD19 can be obtained on the basis of murine and / or human sequences and / or camel sequences and / or llama sequences and / or other suitable sequences, including artificial ones, including those created by modification of mouse and / or human sequences, for example, through the introduction of mutations.
  • the anti-CD3 * CD19 antibody of the invention is chimeric. More preferably, the anti-CD3 * CD19 antibody of the invention is fully human.
  • the recombinant monoclonal bispecific anti-CD3 * CD19 antibody of the invention contains the variable domains of the light and heavy chains of the anti-CD3 antibody, the variable domains of the light and heavy chains of the anti-CD 19 antibody, the linker sequence, the hinge region, the Fc sequence and has two chains connected by disulfide bonds .
  • each chain preferably has the following structure: VL (CD3) -L1-VH (CD19) -L2-VL (CD19) -L3-VH (CD3) -H-CH2-
  • VL (CD3), VL (CD19), VH (CD3) and VH (CD19) are the variable domains of the light and heavy chains of antibodies against CD3 and CD 19, respectively;
  • LI, L2, L3 linker sequences
  • H is a hinge region immunoglobulin IgG
  • CH2-CH3 (IgG) is a constant region of the Fc domain of an IgG immunoglobulin.
  • AHTH-CD3 antibodies are well known in the art.
  • anti-POP antibodies include, but are not limited to, OKTZ, G4.18, 145-2C11, Leu4, NGH3, SCZ, SK7, SP34, RIV-9, and UCHT1.
  • the anti-POP antibody binds to the same epitopes as OCTZ, G4.18, 145-2C11, Leu4, NGH3a, SCZ, SK7, SP34, RIV-9 and UCHT1.
  • One of ordinary skill in the art can obtain additional anti-CD3 antibodies without undue experimentation and, inter alia, determine whether antibodies to the same epitopes are specific as anti-POP antibodies OKTZ, G4.18, 145-2C11, Leu4, NGGZa, VSZ , SK7, SP34, RTV-9, and UCHT1, finding out if the former prevent the binding of the latter to the CD3 antigenic polypeptide.
  • variable domains of the anti-CD3 antibody light and heavy chains exhibiting high specificity and binding affinity for the CD3 antigenic polypeptide can be used within the scope of the present invention.
  • AHTH-CD19 antibodies are also well known in the art, as are methods for their preparation.
  • anti-C019 antibodies include, but are not limited to, HD37, HIB19, SJ25-C1, 4G7-2E3.
  • these methods and antibodies are disclosed in Eurasian application EA200800094, published June 30, 2008.
  • any variable domains of the anti-CD 19 antibody light and heavy chains that exhibit high specificity and binding strength to the CD 19 antigenic polypeptide can be used within the scope of the present invention. However, it is most preferred to use the variable light and heavy chain domains of the antibody in accordance with the present invention.
  • anti-CD19 VL (CD3) and VH (CD3) characterized by the sequences shown in SEQ ID NO: 3 and SEQ ID NO: 4.
  • Fc sequence is a term well known to those skilled in the art — this is the terminal portion of an immunoglobulin molecule that interacts with the Fc receptor on the cell surface and with some proteins of the complement system.
  • immunoglobulins are divided into classes: IgA, IgD, IgE, IgG and IgM, and some of them can be further divided into subclasses (isotypes), for example, IgGl, IgG2, IgG3 and IgG4, IgAl and IgA2.
  • the various classes of immunoglobulins are called [alpha], [delta], [epsilon], [gamma] and [mu], respectively.
  • Four isotypes of human IgG bind various receptors, such as the neonatal Fc receptor, activating gamma Fc receptors, FcgRI, FcgRIIa and FcgRIIIa, inhibiting the FcgRIIb receptor and Clq with different affinities, obtaining different types of activity.
  • the term "Fc sequence" in the framework of the present invention refers, inter alia, to Fc sequences modified to change the affinity for the corresponding receptor.
  • the antibody of the present invention contains an Fc portion to extend the half-life.
  • Such an Fc sequence is preferably of human origin, more preferably is the human Fc sequence of an IgG antibody, more preferably IgG2, even more preferably, is the sequence shown in SEQ ID NO: 5.
  • the selection of an IgG2-type Fc sequence allows one to reduce the effector load due to the Fc sequence and thus reduce the directed toxicity of the antibody of the invention.
  • linker refers to peptide linkers.
  • the length and / or sequence of the linker affects the stability and / or solubility of the bispecific molecule.
  • the linker can increase the flexibility of the resulting binding molecule and / or can improve its binding to the target antigen by reducing steric interference.
  • the length and sequence of the linker depends on the sequence and length of the linked sequences. Methods for testing the suitability of various linkers are well known to the skilled person. For example, the properties of a binding molecule can be easily tested by analyzing its binding affinity using various types of linkers.
  • the stability of the obtained molecule can be measured by methods known in the art, such as, for example, high-performance liquid chromatography, dividing the studied protein material into fractions, depending on the molecular weight of the protein and hydrodynamic characteristics.
  • Linkers that are peptides consisting of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% of small amino acids, such as glycine, series and alanine. Linkers consisting solely of glycine and serine molecules are particularly preferred. Yu Preferably, the linker sequences of the invention are comprised of 5-15 amino acids. More preferably, the LI, L2, L3 linkers of the anti-CD3 * CD19 antibody of the invention are selected from the following sequences:
  • hinge region refers to a sequence that in a natural immunoglobulin binds the CH1 domain to the region of the CH2-CH3 Fc fragment.
  • the hinge region used in the antibody of the invention is preferably homologous to the natural region of the immunoglobulin and typically includes cysteine residues linking the two heavy chains via disulfide bonds, as in natural immunoglobulins.
  • Typical hinge sequences of human and mouse immunoglobulins can be found in ANTIBODY ENGINEERING, a PRACTICAL GUIDE, (Borrebaeck, ed., W. H. Freeman and Co., 1992).
  • Suitable hinge regions of the present invention may be derived from IgGl, IgG2, IgG3, IgG4 and other immunoglobulin isotypes. Most preferably, the IgGl hinge region with the sequence shown in SEQ ID NO: 9 is used in the antibody construct of the invention.
  • variable regions in the construction of the antibody of the invention is of principle principle.
  • the authors carried out work to assess in vitro toxicity for the release of pro-inflammatory cytokines and CD3-mediated antibody cytotoxicity against CD 19+ tumor cells (hereinafter, cytotoxic biological activity) of various variants of the bispecific BiMS format antibody:
  • VH (CD3) -Ll-VH (CD19) -L2-VL (CD19) -L3-VL (CD3) -H-CH2-CH3 (IgG),
  • an anti-CD3 * CD19 antibody is characterized by the sequence of SEQ ID NO: 10.
  • the anti-CD3 * CD19 antibody of the invention is encoded by a nucleic acid, the structure of which can be derived by methods known in the art from the structure of the indicated antibody.
  • the nucleic acid of the invention has a nucleotide sequence deduced from the amino acid sequence shown in SEQ ID NO: 10.
  • the codon composition of the nucleic acid sequence of the invention is selected so that in the selected host cell maximum levels of its transcription and subsequent translation were achieved.
  • the term "nucleic acid" as used in accordance with the present invention preferably refers to DNA. However, this term may also refer to RNA.
  • the host cell may comprise a nucleic acid sequence of the invention stably integrated into the cellular genome.
  • the host cell comprises a nucleic acid sequence of the invention operably integrated for expression in a vector type construct for expression or a linear expression element.
  • expression of an anti-CD3 * CD19 antibody of the invention in a host cell is provided using a vector for expression.
  • expression vector refers to any suitable vector, including chromosomal, extrachromosomal vectors and synthetic nucleic acid vectors containing a suitable set of expression control elements.
  • the vector for expressing the bispecific anti-CD3 * CD19 antibody of the invention is preferably constructed to allow expression of the nucleic acid of the invention in mammalian cells.
  • the specified vector without limitation can also be constructed to ensure expression of the nucleic acid according to the invention in the cells of plants, bacteria, yeast, animals other than mammals.
  • examples of such vectors include derivatives of SV40, bacterial plasmids, phage DNA, baculoviruses, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and vectors from viral nucleic acid (RNA or DNA).
  • Suitable immunoglobulin expression vectors are also disclosed, for example, in McLean et al., Mol. Immunol.
  • a vector for expressing a bispecific anti-CD3 * CD19 antibody of the invention may simultaneously be a cloning vector and have the ability to autonomously replicate in bacterial, yeast and other cells, and also be suitable for the production of a nucleic acid encoding an anti-CD3 * CD19 antibody of the invention, by treating said cloning vector with suitable restriction enzymes.
  • the cloning vector containing a nucleic acid encoding an anti-CD3 * CD19 antibody of the invention does not additionally contain elements for expressing said nucleic acid to enhance its amplification in the host cell.
  • the expression vector is a vector that is suitable for expression of an antibody in bacterial cells.
  • examples of such vectors include BlueScript vectors (Stratagene), pIN vectors, pET vectors (Novagen, Madison WI), and others.
  • the expression vector is a vector that is suitable for expression in the yeast system.
  • Suitable vectors include, for example, vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH.
  • the expression vector is a vector that is suitable for expression of an antibody in a plant. Suitable vectors include, for example, vectors disclosed in RF patent RU2412251, published on 02.20.2011.
  • the expression vector is a vector that is suitable for expression of an antibody in an insect.
  • Suitable vectors include, for example, vectors disclosed in international application publication number WO 2010/025764 of 03/11/2010.
  • the expression vector is a vector that is suitable for expression of the antibody in Chinese hamster cells.
  • the nucleic acid encoding the antibody of the invention may be coupled to any suitable promoter, enhancer and other expression promoting elements. Moreover, these elements are selected based on the type of host cell.
  • replication initiation site from plasmid pBR322 (Product No. 303-3s, New England Biolabs, Beverly, Mass) is applicable to most gram-negative bacteria, while the different replication initiation sites are from SV40, polyomavirus, adenovirus, and vesicular stomatitis virus (VSV) or papillomaviruses (such as HPV or BPV) can be used to clone vectors in mammalian cells.
  • VSV vesicular stomatitis virus
  • HPV or BPV papillomaviruses
  • the transcription termination sequence is usually located 3 '(to the right) from the end of the coding regions of the polypeptide and serves to terminate the transcription. Transcription termination sequences in prokaryotic cells often contain a G-C-rich fragment, followed by a poly T-sequence. Transcription termination sequences can be cloned from a library purchased commercially as part of a vector.
  • a selectable marker gene element encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium.
  • Conventional selectable marker genes encode proteins that (a) confer resistance to antibiotics or other toxins, for example, ampicillin, tetracycline or kanamycin for prokaryotic host cells, (b) supplement auxotrophic cell deficiencies; or (c) supply the necessary nutrients.
  • Preferred breeding markers are the kanamycin resistance gene, the ampicillin resistance gene, and the gene resistance to tetracycline.
  • the neomycin resistance gene can also be used for selection in prokaryotic and eukaryotic host cells.
  • Examples of breeding markers for mammalian cells include dihydrofolate reductase (DHFR) and thymidine kinase.
  • DHFR dihydrofolate reductase
  • Mammalian cell transformants are placed under selection pressure conditions, to which only transformants are adapted for survival, due to the marker present in the vector.
  • the selection pressure is superimposed by culturing the transformed cells under conditions in which the concentration of the selection agent in the medium changes sequentially, which leads to amplification of both the selection gene and the target nucleic acid encoding the antibody of the invention.
  • the amount of nucleic acid encoding the antibody of the invention amplified in this way will produce increased amounts of the antibody.
  • the ribosome binding site is usually present to initiate translation of mRNA.
  • a site is characterized by a Shine-Dalgarno sequence (prokaryotes) or a Kozak sequence (eukaryotes). This element is usually located 3 '(right) from the promoter and 5' (left) from the coding sequence of the expressed polypeptide.
  • the Shine-Dalgarno sequence varies, but is usually polypurine (having a high A-G content). Many Shine-Dalgarno sequences have been identified, each of which can be easily synthesized using the methods presented above and used in the prokaryotic vector.
  • An enhancer sequence can be inserted into a vector to increase transcription in eukaryotic host cells.
  • enhancer sequences of mammalian genes are known (e.g., globin, elastase, albumin, alpha-fetoprotein and insulin). However, usually a virus enhancer should be used.
  • the SV40 enhancer, cytomegalovirus early promoter enhancer, polyomavirus enhancer and adenovirus enhancers are examples of enhancer elements for activating eukaryotic promoters.
  • the components of the vector can be homologous (from the same species and / or strain as the host cell), heterologous (from a species other than the species or strain of the host cell), hybrid (a combination of different sequences from more than one source ), synthetic or native sequences that typically act as regulators of immunoglobulin expression.
  • the sources of the components of the vector can be any prokaryotic or eukaryotic organism, any a vertebrate or invertebrate organism, or any plant, provided that these components are functional in the mechanism of the host cell and can be activated by the mechanism of the host cell.
  • the vector for expressing a bispecific anti-CD3 * CD19 antibody of the invention is a vector for providing heterologous expression in Chinese hamster cells (CHO).
  • a vector for expressing a bispecific anti-CD3 * CD19 antibody of the invention may further comprise a nucleic acid sequence encoding a secretion / localization sequence that can direct the polypeptide into the periplasmic space or into the culture medium.
  • sequences are known in the art and include secretion leaders or signal peptides, organelle targeting sequences (e.g., nuclear localization sequences, ER retention signals, mitochondrial transit sequences, chloroplast transit sequences), membrane localization / anchor sequences (e.g. stop sequences translocations, GPI anchor sequences), etc., which are well known in the field of the present invention.
  • Recombinant expression of an anti-CD3 * CD19 antibody of the invention can be carried out in any suitable host cells known in the art. Moreover, the conditions for expression are selected individually for the type of the host cell and the elements used for heterologous expression.
  • a host cell of the invention may be eukaryotic and prokaryotic.
  • a prokaryotic host cell may be, inter alia, a bacterial cell.
  • the eukaryotic host cell may be, inter alia, a yeast cell, a mammalian cell, a non-mammalian animal cell, for example, an insect cell, a plant cell.
  • eukaryotic host cells of the present invention may be CHO cells, HEK-293 cells, HEK-294 cells, PER.C6 cells, NS0 cells and lymphocyte cells, as well as prokaryotic cells such as E. coli.
  • Some embodiments of the present invention include the introduction of a vector to allow expression of the invention in an in vivo host cell, i.e. into a cell that is part of a living multicellular organism.
  • the specified organism is preferably a person.
  • expression host / vector combinations for expression can be used to express the antibody.
  • a vector taking into account the preservation of its functionality in the host cell in which the specified vector will be introduced.
  • the vector must be compatible with the mechanism of the host cell, so that amplification and expression are possible.
  • expression vectors suitable for eukaryotic hosts include SV40, cattle papilloma virus, adenovirus, adeno-associated virus, cytomegalovirus and retrovirus.
  • Expression vectors that can be used in bacterial hosts include bacterial plasmids such as pBluescript, pGEX2T, pUC, pCRl, pBR322, pMB9 and their derivatives, plasmids like RP4, characterized by a wide list of possible hosts, gtlO and ⁇ 1, phage DNA, represented by various lambda phage derivatives, such as ⁇ 989, and other phage DNAs, such as M13 and single-stranded filamentous phage.
  • Expression vectors that can be used with yeast cells include plasmid 2 ⁇ and its derivatives.
  • a vector that can be used in insect cells is pVL941.
  • a vector combination is used to provide heterologous expression in Chinese hamster cells with cells of a commercially available CHO-M strain (Selexis).
  • a host cell expressing a bispecific anti-CD3 * CD19 antibody of the invention can be obtained by transfection of a parent cell with a vector to allow expression of a bispecific anti-CD3 * CD19 antibody of the invention using any method known in the art, including electroporation, transduction, calcium -phosphate transfection, transfection with cationic lipids, scrape-loading (scraping load) and infection.
  • a method for producing an anti-CD3 * CD19 antibody of the invention comprises culturing said host cell under conditions providing expression of a bispecific anti-CD3 * CD19 antibody of the invention and isolating the resulting product. Moreover, this expression can be carried out both under conditions of a small-scale or large-scale fermenter, and under incubation conditions in flasks, on a rocking chair. Incubation is carried out in a suitable nutrient medium containing sources of carbon and nitrogen and inorganic salts, one of the known methods. Suitable media are commercially available, but can also be prepared independently using components described, for example, in the catalog of the American Type Culture Collection (ATCC).
  • ATCC American Type Culture Collection
  • the term “medium” as used in accordance with the present invention includes any culture medium, solution, solid, semi-solid or solid support that can support or contain any host cell, including bacterial host cells, yeast host cells, cells - insect hosts, plant host cells, mammalian host cells, including CHO cells.
  • An antibody of the invention may be isolated by any method known in the art. However, when choosing a method for isolating the antibody, it is necessary to take into account the features of the expression system used (host cell for expression / vector for expression). So, if the antibody mainly accumulates inside the host cell, it is necessary to choose a method of isolating the product that will ensure its extraction from the host cell. If the antibody accumulates predominantly in the culture fluid, the target product can be isolated from the culture fluid by methods designed to extract antibodies from the culture fluid. For example, an antibody of the invention can be isolated from the culture fluid by standard methods, including, without limitation, chromatography, centrifugation, filtration, extraction, drying, spraying, evaporation or precipitation.
  • An antibody of the invention can be further purified using various techniques known in the art, including chromatography (e.g., ion exchange, affinity, hydrophobic or exclusion), electrophoresis, separation (e.g., ammonium sulfate precipitation), SDS-PAGE or extraction.
  • chromatography e.g., ion exchange, affinity, hydrophobic or exclusion
  • electrophoresis e.g., electrophoresis
  • separation e.g., ammonium sulfate precipitation
  • SDS-PAGE e.g., SDS-PAGE or extraction.
  • the method for purifying an anti-CD3 * CD19 antibody of the invention comprises at least one chromatographic purification step. More preferably, a method for purifying an anti-CD3 * CD19 antibody of the invention comprises centrifugation, affinity chromatography using a protein A sorbent, and high resolution cation exchange chromatography.
  • the anti-CD3 * CD19 antibody of the invention purified according to regulatory requirements is included in the pharmaceutical composition of the invention preferably together with pharmaceutically acceptable carriers and / or diluents.
  • the mechanism of action of the proposed anti-CD3 * CD19 antibody is similar to that described for the anti-POP / anti-C019 antibody, Blinatumomab preparation (MT103); and consists in the activation of a multispecific T-cell cytological response against CD 19+ lymphoma cells.
  • compositions based on antibodies against CD3 * CD19 can be used to treat all hematological cancers (lymphomas and leukemia) of B-cell nature, for example, such as B-cell tumors from precursors of B-lymphocytes, including: lymphoblastic lymphoma / B-cell acute lymphoblastic leukemia from progenitor cells; B-cell tumors from peripheral (mature) B-lymphocytes, including: B-cell chronic lymphocytic leukemia / lymphoma from small lymphocytes (lymphocytic lymphoma); B-cell prolymphocytic leukemia; lymphoplasmacytic lymphoma; splenic lymphoma of the marginal zone; hairy cell leukemia; plasma cell myeloma / plasmacytoma; extranodal B-cell lymphoma of the marginal zone of the MALT type; nodal B-cell lymphoma of the marginal zone; follicular lymphoma
  • composition according to the present invention can be applied directly to animals and humans (for example, locally in the form of injections, including subcutaneous injections).
  • composition according to the present invention is administered parenterally, for example intravenously, intradermally, subcutaneously, intraperitoneally, intramuscularly, buccally, intraorbitally, intracerebrally, intraspinally, intraventricularly, intrathecally, intracerebrally
  • the composition preferably comprises a portion of an aqueous or physiologically compatible solution or suspension of liquid does not adversely affect the balance of electrolytes and / or liquids in patients upon delivery of the target composition to patients.
  • the pharmaceutical composition of the invention is prepared in a form suitable for parenteral administration, preferably for subcutaneous administration, including in the form of sterile aqueous a solution, suspension, emulsion, concentrate for the preparation of an aqueous solution, a lyophilized preparation for the preparation of an aqueous solution, a solution based on a non-aqueous solvent.
  • Pharmaceutically acceptable agents for use in the pharmaceutical composition of the invention include carriers, excipients, diluents, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, tonicity agents, cosolvents , wetting agents, complexing agents, buffering agents, antimicrobial agents and surfactants, as shown, for example, in the "Handbook of Pharmace utical Excipients ”(2" d ed. London: The Pharmaceutical Press; 1994).
  • a carrier or solvent to obtain a sterile aqueous solution in accordance with the present invention, for example, either Hank's solution, or Ringer's solution, or a suitable buffer solution, for example, physiological buffer solution, can be used.
  • the buffers may be conventional buffers such as acetate, citrate, phosphate, bicarbonate buffers or Tris-HCl.
  • Acetate buffer may have a pH of about 4-5.5
  • Tris buffer may have a pH of about 7-8.5. Additional pharmaceutical agents are presented in Remington's Pharmaceutical Sciences, 18th Edition, A.R. Gennaro, ed., Mack Publishing Company, 1990.
  • the anhydrous solvent may be propylene glycol, polyethylene glycol or olive oil or an ester suitable for injection, such as ethyl oleate.
  • a suitable carrier for the purpose of preparing the pharmaceutical composition of the invention is a neutral buffered saline or saline mixed with serum albumin.
  • the pharmaceutical composition of the invention may also contain ascorbic acid, low molecular weight polypeptides, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine, monosaccharides, disaccharides and other carbohydrates including glucose, mannose dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol; salt forming counterions, such as sodium; and / or nonionic surfactants such as tween, pluronic or polyethylene glycol (PEG), alkali metal halides (preferably sodium or potassium chloride), benzalkonium chloride, thimerosal, phenethyl alcohol, methyl paraben, propyl paraben, chlororexidine, sorbic acid, peroxide hydrogen, sorbitan esters, polysorbates such as polysorbate 80, tromethamine, lecit
  • the most preferred adjuvants for use in the pharmaceutical composition of the invention are: sodium phosphate buffer, polysorbate 80 as a surfactant, mannitol as an isotonic agent, and histidine as a stabilizer.
  • excipients can be used in combination with other active ingredients (for example, anti-cancer or anti-inflammatory drugs), provided that they do not cause unwanted effects.
  • active ingredients for example, anti-cancer or anti-inflammatory drugs
  • the pharmaceutical composition of the invention may further comprise one or more lyoprotectants disclosed, for example, in US Pat. Nos. 6,659,540, 6,566,329 and 6,373,716.
  • a lyoprotectant which is a non-reducing sugar, such as sucrose, lactose or trehalose.
  • the amount of lyoprotectant is preferably chosen so that after recovery, the resulting finished form is isotonic.
  • the selected amount of lyoprotectant should be sufficient to prevent an unacceptable amount of protein degradation and / or aggregation after lyophilization.
  • sugar lyoprotectant concentrations e.g., sucrose, lactose, trehalose
  • sugar lyoprotectant concentrations are from about 10 mM to about 400 mM.
  • composition according to the invention if obtained in lyophilized form, can be optionally completed with a pharmaceutically acceptable solvent and / or diluent, for example, physiological water solution and other commonly used pharmaceutically acceptable solvents.
  • a pharmaceutically acceptable solvent and / or diluent for example, physiological water solution and other commonly used pharmaceutically acceptable solvents.
  • compositions may contain a therapeutically effective amount of an antibody of the invention.
  • therapeutically effective amount refers to that amount of an antibody of the invention that is effective for the necessary periods of time to achieve the desired therapeutic result, and any toxic or harmful effects of the antibody should be outweighed by therapeutically beneficial effects. from this antibody, which in a preferred embodiment of the present invention is at least one of leduyuschego: symptom relief, healing or increase the speed of recovery.
  • the therapeutically effective amount of an antibody of the invention can vary according to factors such as the condition of the disease, age, gender, and weight of the individual, the ability of the antibody to induce the desired response specifically in the individual, the presence of concomitant diseases, route of administration, frequency of administration, individual treatment regimen.
  • the attending physician can decide on the number of antibodies according to the invention, which it is advisable to treat each patient individually. Moreover, the attending physician may first administer small doses of the antibody of the invention and, according to the patient’s response, adjust its amount. Dosage ranges are from about 0.5 ⁇ g / kg to about 2 mg / kg, depending on the above factors. In this case, preferably, the pharmaceutical composition according to the invention contains 10-100 ⁇ g of antibody.
  • composition according to the invention is prepared, dosed and administered in accordance with the principles of good medical practice. Standard pharmaceutical formulation methods are known to those skilled in the art (Remington 1995).
  • a method of treating B-cell disease or B-cell depletion, or slowing the development of a pathological condition associated with B-cell disorders of the present invention includes administering to a patient in need thereof an effective amount of an antibody of the invention or a pharmaceutical composition of the invention. Moreover, in a preferred embodiment of the present of the invention, the antibody is administered subcutaneously to the patient. Moreover, the anti-CD3 * CD19 antibody of the invention can be administered to a patient in combination with another drug, including for at least one of the following purposes: to enhance the therapeutic effect against B-cell disease, to reduce side effects during treatment B-cell disease, to alleviate the symptoms of B-cell disease.
  • the duration of therapy using the combination of the present invention varies depending on the severity of the disease to be treated and the condition, and also depending on the potential response of each individual patient. It is assumed that the duration of therapy is determined by the severity of the symptoms. Ultimately, the attending physician decides on the appropriate duration of therapy using the combination of the present invention.
  • an antibody according to the invention can be obtained using technologically simple known recombinant methods, commercially available agents (vector, host cell, medium) and traditional methods for the isolation and purification of antibodies (Example 1);
  • a pharmaceutical composition can be obtained in a technologically simple way, including in a lyophilized form suitable for subsequent reconstitution with traditional diluents (Example 2).
  • the authors of the present invention also experimentally demonstrated, in comparison with MT103, a significantly increased half-life (T1 / 2) and exposure (AUC (O-inf)) of the anti-CD3 * CD19 antibody of the invention, while maintaining the maximum peak concentration (Cxx) when administered intravenously, and also increased bioavailability of antibodies against CD3 * CD19 according to the invention with both intravenous and subcutaneous administration (Example 4). Additionally, the authors of the present invention experimentally confirmed a higher affinity of the antibodies of the invention for CD3 and CD 19 and its higher antitumor activity when administered subcutaneously in comparison with MT103 (Examples 3 and 5).
  • the gene encoding the anti-CD3 * CD19 antibody chain was constructed by annealing the overlapping chemically synthesized oligonucleotides.
  • the sequence of the target gene was cloned into the commercially available vector pUC 19, whereby the vector pAPG_GNR047 was obtained, which was used for further work.
  • pAPG_GNR047 vector After treating the pAPG_GNR047 vector with Hindlll, Xbal (New Ingland Biolabs) restriction endodesoxyribonucleases forming sticky ends, a 2235 bp fragment was then ligated, which was then ligated with the Hindlll and Xbal linearized pSTlOl expression vector.
  • the resulting plasmid pRA1451 was verified by restriction mapping.
  • the construction scheme of the expression vector pRA1451 is shown in FIG. 2.
  • the resulting plasmid pRA1451 encoding a polypeptide with the sequence shown in SEQ ID NO: 10, is characterized by the following features:
  • - pA is a synthetic polyadenylation signal.
  • - contains unique recognition sites for the following restriction endonucleases: Accl (6490 no), Agel (460 no), Apal (995 no), BmgBI (3270 acting), Bsml (7269 acting), EcoRV (6457 no), Hindlll (1590 no), Notl ( 11146 no), Pfol (11021 no), Pmll (5699 no), Spel (4622 no), Swal (6466 no), Tthl 1 II (10585 no).
  • Transfection was performed using a commercially available strain of CHO-M (Selexis).
  • the selection of the producer cell line is due to the need to form an optimal glycosylation profile in the synthesis of human proteins, as well as their stability, safety and the possibility of using suspension culture conditions for this cell line, which are the most important parameters for the production of therapeutic antibodies.
  • Cultivation was carried out in fed-batch mode using BalanCD CHO Growth A nutrient medium (Irvine Scientific) and CellBoost 3 (HyClone) nutrient supplement for 10 days at 37 ° ⁇ , 5% ⁇ 0 2 in the gas phase of the incubator. After cultivation, the culture fluid was clarified by centrifugation and transferred to the selection.
  • BalanCD CHO Growth A nutrient medium Irvine Scientific
  • CellBoost 3 HyClone
  • Example 2 Pharmaceutical composition based on antibodies against CD3 * CD19.
  • compositions of the following composition were used: 0.7 mg / ml anti-CD3 * CD19 antibody of the invention (hereinafter GNR-047), 150 mM sodium chloride, 1.8% mannitol, 20 mM sodium phosphate, 0.01% polysorbate 80.
  • the purification conditions of the anti-CD3 * CD19 antibody of the invention at the last chromatographic stage of the process are selected so that the target protein is eluted from the sorbent in the form of a concentrated substance containing all the required components of the final formulation.
  • an antibody solution with a concentration of about 5 mg / ml (the concentrated solution obtained in Example 1 after chromatographic purification) was diluted to the required concentration of 0.7 mg / ml using the buffer of the finished dosage form with stirring.
  • the resulting solution was subjected to sterilizing filtration using a filter with a pore diameter of 0.22 ⁇ m and poured into sterile vials to store the composition and subsequent experiments.
  • a solution containing anti-CD3 * CD19 antibodies of the invention in a finished buffer 150 mM sodium chloride, 1.8% mannitol, 20 mm sodium phosphate, 0.01% polysorbate 80
  • a finished buffer 150 mM sodium chloride, 1.8% mannitol, 20 mm sodium phosphate, 0.01% polysorbate 80
  • sodium chloride and mannitol were used as crystallizing components, the presence of which allows the formation of a tablet, and mannitol also played the role of a stabilizer during lyophilization.
  • the resulting lyophilic preparation was stored at 4C in sealed vials.
  • Water for injection was used as a solvent for reconstituting the lyophilized composition.
  • 0.5 ml of the solvent was added to the vial containing the lyophilized antibody composition at room temperature and gently mixed by shaking until it was completely dissolved.
  • Bacteriostatic water for injection can also serve as a solvent, dissolution in which allows the drug to be reused within 7 days.
  • the biological activity of the obtained antibody was evaluated by determining the binding constants in a competitive analysis on cells of the Raja line CD3- / CD19 + (Raji, ATCC® CCL-86) and Dzhurkat CD3 + / CD19- (Jurkat, ATCC® TIB-152) from the ATCC collection.
  • Antibody MT-103 (blinatumomab) was used as a comparison drug. After incubation with the target molecules in successive 10-fold dilutions from 100 nM to 0.1 nM, a competing antibody (HD37 or OCTZ) was added to the cells at a concentration of 6 nM. Cells were washed with pH 7.0 sodium phosphate buffer and stained with anti-Human-FITS antibodies. Stained cells were analyzed by FACS Calibur.
  • the table shows that the GNR-047 antibody binds to both CD3 and CD 19, and in both cases it is more effective than the MTUZ comparison drug. Such low, in comparison with the comparison drug, IC50 values can be explained by the presence of 2 valencies for each specificity (CD3 and CD 19
  • rats of the Sprague Dawley line were used (Pushchino Kennel of Laboratory Animals, branch of the Institute of Bioorganic Chemistry named after Academicians MM Shemyakin and Yu. A. Ovchinnikov of the Russian Academy of Sciences) weighing about 400 g, 3 rats per group.
  • test antibody GNR-047 or MT-103 was administered intravenously at a dose of 0.5 mg / kg or subcutaneously at a dose of 2.0 mg / kg to each rat. Blood samples were taken at certain intervals after injection, starting from 5 min, and the concentration of the drugs in the blood plasma was determined using enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • the parameter is calculated taking into account the dose difference.
  • TT necessary to reduce the concentration of the drug in blood plasma by 50% as a result of elimination;
  • Sshah the highest concentration of the drug in the blood plasma;
  • AUQo-t is the area bounded by the pharmacokinetic curve and the abscissa axis in the time interval from the moment of drug administration until the last blood sample is taken;
  • AUQo-inf) the area bounded by the pharmacokinetic curve and the abscissa axis, extrapolated in time from the moment of drug administration to infinity; / a - part of the dose of the drug (in%), which reached the systemic circulation after extravascular administration.
  • Example 5 Comparison of the antitumor activity of GNR-047 and MT 103 in a model of a tumor xenograft of Raji cells (Raji) in NOD / SCID mice during reconstitution of human PBMC
  • the aim of the study was to compare the efficacy of GNR-047 and MT103 preparations in NOD / SCID mice (Taconic, Denmark) at several dose levels, on a Raja tumor cell xenograft model with simultaneous injections of human peripheral blood mononuclear cells (MCPC) to immunodeficient NOD / SCID mice .
  • MCPC peripheral blood mononuclear cells
  • Cells of the Raja line human Burkitt’s lymphoma
  • Injected solutions were prepared by diluting the GNR-047 solution (composition) obtained in Example 2 (0.7 mg / ml) or MT103 (0.52 ⁇ g / ml) in 0.9% saline to obtain a concentration of 5 ⁇ g / ml (dose 1 ⁇ g) or 0.5 ⁇ g / ml (dose 0.1 ⁇ g).
  • the experimental groups are described in table 3.
  • Body weight was determined on day 0 and was subsequently recorded three times a week until day 48.
  • Tumor volume was monitored 3 times a week from day 3 until the end of the study by measuring the large and small diameter of the tumor with a barbell. Based on the diameters, the tumor volume was calculated using the following formula:
  • Tumor growth was significantly inhibited or suppressed in all study groups treated with GNR-047 or MT 103 (groups 3-9) compared with control group 2 treated with NPF. Moreover, in all the studied groups treated with GNR-047 or MT 103, inhibition of tumor growth was statistically significant (p ⁇ 0.05).
  • Table 5 shows the tumor sizes for groups 1, 2, 4, 8, and 9, and the corresponding comparative graphs that allow us to estimate the size of the tumor during intravenous and subcutaneous administration (for groups 4, 8, and 9) are shown in Fig. 7.
  • the present invention can be used in medicine for the treatment of B-cell diseases or depletion of B-cells, including B-lymphoblastic lymphoma / B-cell acute lymphoblastic leukemia from progenitor cells; B-cell tumors from peripheral (mature) B-lymphocytes, including: B-cell chronic lymphocytic leukemia / lymphoma from small lymphocytes (lymphocytic lymphoma); B-cell prolymphocytic leukemia; lymphoplasmacytic lymphoma; splenic lymphoma of the marginal zone; hairy cell leukemia; plasma cell myeloma / plasmacytoma; extranodal B-cell lymphoma of the marginal zone of the MALT-type; nodal B-cell lymphoma of the marginal zone; follicular lymphoma; mantle cell lymphoma; diffuse B-large cell lymphoma; mediastinal diffuse B-large cell lymphoma; primary exud

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne la biotechnologie et notamment peut être utilisée en médecine humaine et en industrie pharmaceutique pour traiter la maladie aux lymphocytes B, l'exténuation des lymphocytes B ou le développement ralenti, l'état pathologique associé aux troubles de lymphocytes B. L'anticorps bispécifique qui se lie de façon spécifique à CD3 et CD19 comprend deux chaînes reliées par des liens bisulfure. Chaque chaîne comprend des domaines variables des chaînes lourde et légère des anticorps contre CD3 et CD19, des séquences de liaisons, une région charnière d'immunoglobuline IgG et une région constante du domaine Fc de l'immunoglobuline IgG. L'anticorps est obtenu au moyen de technologiques d'ADN recombinants utilisation un acide nucléique codant pour un anticorps et/ou un vecteur le contenant qui est introduit dans la cellule hôte. Le procédé de production de l'anticorps comprend au moins la culture de la cellule hôte et l'extraction du produit cible. Le procédé de purification d'anticorps comprend au moins le stade de chromatographie. L'anticorps est utilisé pour traiter une maladies de lymphocytes B, l'exténuation des lymphocytes B ou le développement ralenti, l'état pathologique associé aux troubles de lymphocytes B. La composition pharmaceutique correspondante comprend cet anticorps et le véhicule pharmaceutiquement acceptable. La méthode de traitement de ces maladies consiste à administrer au patient qui en a besoin une quantité thérapeutiquement efficace de l'anticorps. L'invention permet d'améliorer le confort pratique d'utilisation de la thérapie anti-CD3*CD19, son effet cytotoxique renforcé et sa biodisponibilité élevée même lors de l'administration sous-cutanée.
PCT/RU2016/000827 2015-12-01 2016-11-29 Anticorps bi-spécifiques contre cd3*cd19 WO2017095267A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201890805A EA036905B1 (ru) 2015-12-01 2016-11-29 Биспецифические антитела против cd3*cd19

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2015151459A RU2651776C2 (ru) 2015-12-01 2015-12-01 Биспецифические антитела против cd3*cd19
RU2015151459 2015-12-01

Publications (1)

Publication Number Publication Date
WO2017095267A1 true WO2017095267A1 (fr) 2017-06-08

Family

ID=58797475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2016/000827 WO2017095267A1 (fr) 2015-12-01 2016-11-29 Anticorps bi-spécifiques contre cd3*cd19

Country Status (3)

Country Link
EA (1) EA036905B1 (fr)
RU (1) RU2651776C2 (fr)
WO (1) WO2017095267A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112010982A (zh) * 2020-08-31 2020-12-01 重庆金迈博生物科技有限公司 一种抗gpc3/cd3双特异性抗体及其应用
CN114364698A (zh) * 2019-08-21 2022-04-15 吉尼瑞姆股份公司 结合cd3的互补决定区和含所述cdr的双特异性抗原结合分子
WO2022165171A1 (fr) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions et méthodes de traitement du syndrome de libération de cytokines
WO2023062188A1 (fr) * 2021-10-15 2023-04-20 Amgen Research (Munich) Gmbh Administration sous-cutanée d'anticorps mis en contact avec des lymphocytes t se liant à cd19
WO2023201226A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
WO2024173830A2 (fr) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Cellules nk induites sensibles à des anticorps bispécifiques cd3/taa

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3380126A4 (fr) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. Conjugués anticorps-médicament comprenant des lieurs ramifiés et procédés connexes
AU2019266406A1 (en) 2018-05-09 2020-11-26 Ligachem Biosciences Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947646B2 (en) * 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507381A (en) * 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
ATE346866T1 (de) * 2001-09-14 2006-12-15 Affimed Therapeutics Ag Multimerische, einzelkettige, tandem-fv- antikörper
ME03480B (fr) * 2008-11-07 2020-01-20 Amgen Res Munich Gmbh Traitement de la leucémie lymphoblastique aiguë
DK2493503T4 (da) * 2009-10-27 2021-04-12 Amgen Res Munich Gmbh Doseringsplan for administrering af et cd19xcd3-bispecifikt antistof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947646B2 (en) * 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NAGORSEN DIRK ET AL.: "Immunomodulatory therapy of cancer with T cell -engaging BiTE antibody blinatumomab", EXPERIMENTAL CELL RESEARCH, vol. 317, 2011, pages 1255 - 1260, XP028205663 *
REUSCH UWE ET AL.: "A tetravalent bispecific TandAb ( CD 19/ CD 3), AFM11, efficiently recruits T cells for the potent lysis of CD 19+ tumor cells.", MABS, vol. 7, no. 3, June 2015 (2015-06-01), pages 584 - 604, XP009184710 *
STEIN ANDREAS ET AL.: "Cation exchange chromatography in antibody purification: pH screening for optimised binding and HCP removal", JOURNAL OF CHROMATOGRAPHY B, vol. 848, 2007, pages 151 - 158, XP005922836 *
ULRICH H.WEIDLE ET AL.: "Tumor-antigen-binding bispecific antibodies for cancer treatment.", SEMINARS IN ONCOLOGY, vol. 41, no. 5, October 2014 (2014-10-01), pages 653 - 660, XP055250095 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364698A (zh) * 2019-08-21 2022-04-15 吉尼瑞姆股份公司 结合cd3的互补决定区和含所述cdr的双特异性抗原结合分子
CN114364698B (zh) * 2019-08-21 2024-05-28 吉尼瑞姆股份公司 结合cd3的互补决定区和含所述cdr的双特异性抗原结合分子
CN112010982A (zh) * 2020-08-31 2020-12-01 重庆金迈博生物科技有限公司 一种抗gpc3/cd3双特异性抗体及其应用
CN112010982B (zh) * 2020-08-31 2023-06-27 重庆金迈博生物科技有限公司 一种抗gpc3/cd3双特异性抗体及其应用
WO2022165171A1 (fr) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions et méthodes de traitement du syndrome de libération de cytokines
WO2023062188A1 (fr) * 2021-10-15 2023-04-20 Amgen Research (Munich) Gmbh Administration sous-cutanée d'anticorps mis en contact avec des lymphocytes t se liant à cd19
WO2023201226A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
WO2024173830A2 (fr) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Cellules nk induites sensibles à des anticorps bispécifiques cd3/taa

Also Published As

Publication number Publication date
RU2015151459A (ru) 2017-06-06
RU2651776C2 (ru) 2018-04-23
EA036905B1 (ru) 2021-01-13
EA201890805A1 (ru) 2018-08-31

Similar Documents

Publication Publication Date Title
WO2017095267A1 (fr) Anticorps bi-spécifiques contre cd3*cd19
US11352442B2 (en) Heterodimeric antibodies that bind CD3 and CD38
US10227410B2 (en) Heterodimeric antibodies that bind CD3 and PSMA
JP6484634B2 (ja) Ｉｌ−１５ヘテロ二量体タンパク質及びその用途
US11111305B2 (en) Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
CN113166220A (zh) 创新细胞因子前药
JP2020529832A (ja) ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
KR20200118080A (ko) Nkg2d 수용체를 표적화하는 항체 가변 도메인
JP2018500025A (ja) ５ｔ４及びｃｄ３に対する３つの結合ドメインを含む融合タンパク質
AU2005248276A1 (en) Glycosylated immunoglobulin and immunoadhesin comprising the same
KR102477536B1 (ko) 재조합 정맥내 면역글로불린(rIVIG) 조성물 및 이의 제조 및 사용 방법
CN114222764A (zh) 可优先结合IL-2Rα的IL-2融合蛋白
US20230002466A1 (en) Engineered interleukin-2 receptor beta agonists
JP2024028761A (ja) 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
KR20200132919A (ko) 이중특이적 egfr/cd16 항원-결합 단백질
KR102399028B1 (ko) 이중-특이적 항원-결합 폴리펩티드
JP2024513951A (ja) 抗ｃｄ２０抗体及びｃａｒ－ｔ構造
CA3193009A1 (fr) Methodes et compositions pour le traitement du glioblastome
JP2023542049A (ja) インターロイキン－２ムテイン及びその使用
WO2023045977A1 (fr) Mutant de l'interleukine-2 et sa protéine de fusion
CN118451097A (zh) 新型il27受体激动剂及其使用方法
KR20230160389A (ko) 이중 특이성 다기능 융합 폴리펩티드
CN114712494B (zh) 一种靶向pd-1的多功能抗体的组合物
CN114712495B (zh) 一种多功能抗体的组合物
TW202428610A (zh) 標靶ＴＮＦα和ＩＬ－２３的抗體及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16871130

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 201890805

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16871130

Country of ref document: EP

Kind code of ref document: A1